{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:49:26Z","timestamp":1754261366904,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s10637-021-01142-1","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T03:27:55Z","timestamp":1630121275000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5290-9660","authenticated-orcid":false,"given":"Yannis","family":"Metaxas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Fudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"1142_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/1535-7163.MCT-16-0172","volume":"15","author":"G Santamaria Nunez","year":"2016","unstructured":"Santamaria Nunez G, Robles CM, Giraudon C, Martinez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly JM (2016) Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol Cancer Ther 15:1\u201314","journal-title":"Mol Cancer Ther"},{"key":"1142_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bjc.2017.205","volume":"117","author":"C Belgiovine","year":"2017","unstructured":"Belgiovine C, Bello E, Liguori M, Craparotta I, Mannarino L, Paracchini L, Beltrame L, Marchini S, Galmarini CM, Mantovani A, Frapolli R, Allavena P, D\u2019Incalci M (2017) Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br J Cancer 117:628\u2013638","journal-title":"Br J Cancer"},{"key":"1142_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA, Peters S, Ponce S, Fern\u00e1ndez C, Alfaro V, G\u00f3mez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Mart\u00ednez M, Delord J-P, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D\u2019Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L (2020) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21:645\u2013654","journal-title":"Lancet Oncol"},{"key":"1142_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.annonc.2019.12.009","volume":"31","author":"Metaxas Y, Fruh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R, Swiss Group for Clinical Cancer R","year":"2020","unstructured":"Metaxas Y, Fruh M, Eboulet EI, Grosso F, Pless M, Zucali PA, Ceresoli GL, Mark M, Schneider M, Maconi A, Perrino M, Biaggi-Rudolf C, Froesch P, Schmid S, Waibel C, Appenzeller C, Rauch D, von Moos R, Swiss Group for Clinical Cancer R (2020) Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17\/16). Ann Oncol 31:495\u2013500","journal-title":"Ann Oncol"},{"key":"1142_CR5","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1200\/JCO.2018.78.6558","volume":"36","author":"C Cruz","year":"2018","unstructured":"Cruz C, Llop-Guevara A, Garber JE, Arun BK, Perez Fidalgo JA, Lluch A, Telli ML, Fernandez C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Perez de la Haza A, Domchek SM, Antolin S, Vahdat L, Tung NM, Lopez R, Arribas J, Vivancos A, Baselga J, Serra V, Balmana J, Isakoff SJ (2018) Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. J Clin Oncol 36:3134\u20133143","journal-title":"J Clin Oncol"},{"key":"1142_CR6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-11-0252","volume":"10","author":"DG Soares","year":"2011","unstructured":"Soares DG, Machado MS, Rocca CJ, Poindessous V, Ouaret D, Sarasin A, Galmarini CM, Henriques JA, Escargueil AE, Larsen AK (2011) Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther 10:1481\u20131489","journal-title":"Mol Cancer Ther"},{"key":"1142_CR7","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/1078-0432.CCR-12-1513","volume":"18","author":"A Vidal","year":"2012","unstructured":"Vidal A, Munoz C, Guillen MJ, Moreto J, Puertas S, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A (2012) Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res 18:5399\u20135411","journal-title":"Clin Cancer Res"},{"key":"1142_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5414\/CPP39517","volume":"39","author":"M Baumh\u00e4kel","year":"2001","unstructured":"Baumh\u00e4kel M, Kasel D, Rao-Schymanski RA, B\u00f6cker R, Beckurts KT, Zaigler M, Barthold D, Fuhr U (2001) Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 39:517\u2013528","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1142_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/CAD.0b013e328323a7a8","volume":"20","author":"V Masek","year":"2009","unstructured":"Masek V, Anzenbacherov\u00e1 E, Machov\u00e1 M, Brabec V, Anzenbacher P (2009) Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs 20:305\u2013311","journal-title":"Anticancer Drugs"},{"key":"1142_CR10","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","volume":"20","author":"ME Elez","year":"2014","unstructured":"Elez ME, Tabernero J, Geary D, Macarulla T, Kang SP, Kahatt C, Pita AS, Teruel CF, Siguero M, Cullell-Young M, Szyldergemajn S, Ratain MJ (2014) First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid Tumors. Clin Cancer Res 20:2205\u20132214","journal-title":"Clin Cancer Res"},{"key":"1142_CR11","first-page":"392P","volume":"27","author":"T Sauri","year":"2016","unstructured":"Sauri T, Awada A, Calvo E, Moreno V, Szyldergemajn S, Elez E, Barthelemy P, Boni V, Doger B, Fernandez Teruel C, Soto-Matos A, Tabernero J, Aftimos P (2016) Lurbinectedin (PM01183) administered once (C1) every 3 weeks (q3w) in combiantion with capecitabine (XEL) in patients (pts) with metastatic breast (MBC), colorectal (CRC) or pancreatic (PaC) cancer. Eur J Cancer 27:392P","journal-title":"Eur J Cancer"},{"key":"1142_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2217\/fon-2018-0597","volume":"15","author":"AF Farago","year":"2019","unstructured":"Farago AF, Drapkin BJ, Lopez-Vilarino de Ramos JA, Galmarini CM, Nunez R, Kahatt C, Paz-Ares L (2019) ATLANTIS: a Phase III study of lurbinectedin\/doxorubicin versus topotecan or cyclophosphamide\/doxorubicin\/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line. Future Oncol 15:231\u2013239","journal-title":"Future Oncol"},{"key":"1142_CR13","doi-asserted-by":"crossref","unstructured":"Ponce Aix S, Cot\u00e9 G, Falc\u00f3n A, Jimenez-Aguilar E, Lin JJ, S\u00e1nchez Sim\u00f3n I, Flor MJ, N\u00fa\u00f1ez R, Jim\u00e9nez AM, Jim\u00e9nez E, Siguero M, Kahatt C, Zeaiter A, Paz-Ares L (2020) OA11.04 - Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial IASLC; 2020 World Conference on Lung Cancer; January 21, Singapore (virtual meeting)","DOI":"10.1016\/j.jtho.2021.01.314"},{"key":"1142_CR14","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/j.ejca.2009.04.002","volume":"45","author":"C Sessa","year":"2009","unstructured":"Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D\u2019Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L (2009) Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer 45:2116\u20132122","journal-title":"Eur J Cancer"},{"key":"1142_CR15","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/s10637-013-9942-y","volume":"31","author":"C Sessa","year":"2013","unstructured":"Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernandez-Teruel C, Gianni L (2013) Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Invest New Drugs 31:1236\u20131243","journal-title":"Invest New Drugs"},{"key":"1142_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s10637-010-9559-3","volume":"30","author":"L Vidal","year":"2012","unstructured":"Vidal L, Magem M, Barlow C, Pardo B, Florez A, Montes A, Garcia M, Judson I, Lebedinsky C, Kaye SB, Salazar R (2012) Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs 30:616\u2013628","journal-title":"Invest New Drugs"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01142-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01142-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:47Z","timestamp":1678509527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01142-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1142"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01142-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committees of participating centers in Switzerland and the U.K. The study was conducted in full accordance with the principles of the World Medical Association Declaration of Helsinki, the International Conference of Harmonisation, and all applicable local guidelines and regulations on good clinical practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients provided written informed consent about participation in this study and the use of collated data. No individual patient data are included in this article that could be used to identify any individual.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yannis Metaxas received institutional grant for clinical trials from PharmaMar S.A. and Bristol-Meyers Squibb; travel grant from PharmaMar S.A.; and advisory board from PharmaMar S.A.. Carmen Kahatt, Vicente Alfaro, Salvador Fudio and Ali Zeaiter are employees and stock owners of Pharma Mar, S.A. Ruth Plummer received fees as advisory board member from Pierre Faber, Bayer, Novartis, Biosceptre, BMS, Cybrexa, Ellipses, CV6 Therapeutics, Astex Therapeutics, Medivir, GammaDelta Therapeutics, and Sanofi Aventis. Roger von Moos received fees as advisory board member for Astra Zeneca, BMS, Celgene, MSD, Pierre Fabre, Pharmamar S.A., Polyphor, Roche, Vifor, and speaker honoraria from Amgen. Martin Forster received research funding (institutional) from AstraZeneca, Boehringer Ingelheim, MSD and Merck and conducted consulting and advisory services, speaking or writing engagements, or public presentations for Achilles, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pfizer, PharmaMar, S.A. Roche and Takeda. Anastasios Stathis received Institutional grants for clinical trials from PharmaMar S.A., Merck, Bayer, Roche, Novartis, Pfizer, ADC Therapeutics, MEI Pharma and Eli Lilly; advisory board from Roche and Janssen; consultant fees from Bayer and Eli Lilly. Other authors declared no conflict of interest\/competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}}]}}